Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1699979

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the cost-benefit analysis of the T1DE pilot schemes carried out by NHS England.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20896
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20897 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699980

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she (a) has made and (b) plans to make an assessment of the potential merits of funding options to ensure the sustainability of T1DE services beyond the pilot phase.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20897
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20896 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700037

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of NHS consultants carried out work in the private sector in the most recent financial year for which data is available.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20900
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 10:23:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688963

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Diseases: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) NICE and (b) NHS England on encouraging the adoption of new treatments for (i) sickle cell disease and (ii) beta-thalassaemia.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13899
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), related to patient access to new treatments.</p><p> </p><p>The NICE appraises all new licensed medicines, and its recommendations are developed independently in line with its established methods and processes, on the basis of an assessment of the available evidence, and through extensive engagement with stakeholders. NHS England is legally required to fund treatments recommended in NICE technology appraisal guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/02/2024 16:13:28 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688964

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with NICE on developing its methodologies to ensure future access to (a) innovative one-time treatments and (b) cell and genetic therapies.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13900
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13901 13902 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688965

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the (a) National Institute for Health and Care Excellence (NICE) and (b) Chancellor of the Exchequer on the application of NICE's evaluation methods to support value assessment for one-off curative treatments for which health gains are accrued over time.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13901
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13900 13902 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688966

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the National Institute for Health and Care Excellence on updates in the way that it assesses medicines that reduce health inequalities.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13902
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13900 13901 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1689034

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with type 1 diabetes use (a) finger-pricking monitoring and (b) continuous monitoring to track their glucose levels.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13903
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target. As a result of the recent National Institute for Health and Care Excellence guidance that also recommended that insulin dependent patients with type 2 diabetes should benefit from flash or continuous glucose monitoring devices, we are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13904 question first answered 21/02/2024 16:21:48 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1689035

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with type 1 diabetes use real time continuous glucose monitoring to manage their diabetes.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13904
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target. As a result of the recent National Institute for Health and Care Excellence guidance that also recommended that insulin dependent patients with type 2 diabetes should benefit from flash or continuous glucose monitoring devices, we are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13903 question first answered 21/02/2024 16:21:48 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1689037

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce waiting times for (a) diagnosis and (b) treatment for young people with cancer.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13905
	answer	answer is ministerial correction date of answer 23/02/2024 answer text <p>Reducing waiting times for the diagnosis and treatment for young people with cancer is a priority for the Government. On 6 February 2024 the Department announced the setup of a new Children and Young People Cancer Taskforce to progress our mission to deliver world-leading cancer services. This dedicated work, focusing on cancers affecting children and young people, will explore detection, diagnosis and genomic testing and treatment, as well as research and innovation.</p><p>Several organisations across England, including the Department, are taking steps to increase diagnosis rates. This includes setting stretching ambitions, supporting general practices (GPs) in referring patients, expanding diagnostic capacity, and enabling more precise diagnosis through technology.</p><p>The National Institute for Health and Care Excellence’s guidance underpinning cancer referrals sets out detailed guidance for GPs on the symptoms of cancer in children and young people, recommending very urgent referral, an appointment within 48 hours, for those presenting with a range of potential cancer.</p><p>Backed by £2.3 billion of capital funding, the Department is expanding diagnostic capacity across the National Health Service by rolling out more community diagnostic centres (CDCs), delivering vital tests, scans and checks. With 153 CDCs open already and up to 160 set to open by March 2025, these offer millions of patients the chance to access quicker, more convenient checks outside of hospitals, with capacity prioritised for cancer.</p><p>In addition, the NHS now offers all children and young people with cancer whole genome sequencing, to enable more comprehensive and precise diagnosis, and access to more personalised treatments.</p><p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/02/2024 14:58:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth